Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

You may be eligible if

• Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype
• * Indolent
• * Follicular small cleaved cell
• * Follicular mixed cell
• * Small lymphocytic
• * Mucosa-associated lymphoid tissue (MALT)
• * Monocytoid B-cell
• * Waldenstrom's macroglobulinemia
• * Aggressive
• * Follicular large cell
• * Diffuse large cell
• * Immunoblastic
• * Mantle cell
• * Ki-1+ NHL
• * Peripheral T-cell
• * Angiocentric and angioimmunoblastic
• * Transformed lymphoma
• Bidimensionally measurable disease
• No more than 3 prior treatment regimens as follows:
• * Primary radiotherapy is 1 regimen
• * Combined therapy with radiotherapy and chemotherapy is 1 regimen
• * Alternating therapy is 1 regimen
• No known brain metastases
• Performance status - ECOG 0-2
• Performance status - Karnofsky 50-100%
• WBC count at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Bilirubin normal
• SGOT/SGPT no greater than 2.5 times upper limit of normal
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No neuropathy greater than grade 1
• No history of allergy to platinum compounds or antiemetics
• No uncontrolled illness
• No active infection
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No concurrent colony-stimulating factors during first course of therapy
• At least 4 weeks since prior chemotherapy
• At least 4 weeks since prior radiotherapy
• No other concurrent investigational drugs
• No concurrent antiretroviral therapy for HIV-positive patients